GREGoRi Innovation Projects (U01 Clinical Trial Optional)
NHGRI will fund pilot studies using innovative molecular technologies, beyond standard DNA sequencing, to identify genes or variants causing rare genetic disorders, with applications opening in 2026.
Funder: National Institutes of Health
Due Dates (Anticipated): November 2026 | November 2025
Funding Amounts: Award size not yet specified; cooperative agreement (U01) mechanism; details to be announced in the official NOFO.
Summary: Supports proof-of-concept research on novel molecular strategies to identify genes or variants underlying rare genetic disorders, emphasizing approaches beyond standard DNA sequencing.
Key Information: This is a forecasted opportunity; official NOFO and full details will be published in 2025.
Description
The National Human Genome Research Institute (NHGRI) at the NIH plans to launch a new initiative to fund proof-of-concept studies aimed at advancing strategies for identifying genes or variants responsible for rare genetic disorders. This program encourages research that employs innovative molecular technologies as alternatives to the current standard of DNA sequencing-based methods. Projects could include pilot studies using multi-omics, RNA-seq, methylation, or other emerging molecular approaches as the initial investigative step. Successful technologies from these studies may later be integrated into the NHGRI Technology Integration Center. The funding mechanism will be a U01 cooperative agreement, and clinical trials are optional.
